Eli Lilly and Company (NYSE: LLY) has successfully completed its acquisition of Morphic Holding, Inc. (NASDAQ: MORF), a biopharmaceutical company developing oral integrin therapies for treating serious chronic diseases. The acquisition, valued at $57 per share, broadens Lilly's immunology pipeline, particularly in the field of inflammatory bowel disease (IBD).
Key highlights include:
- Acquisition of Morphic's oral integrin therapies, including MORF-057, a selective oral small molecule inhibitor of α4β7 integrin for IBD
- Reinforcement of Lilly's strategy to deliver first or best-in-class therapies in gastroenterology
- Potential for researching combination treatments to better serve patients
- Delisting of Morphic's common stock from The Nasdaq Global Market
Eli Lilly and Company (NYSE: LLY) has entered a definitive agreement to acquire Morphic Holding (NASDAQ: MORF) for $57 per share in cash, totaling approximately $3.2 billion. This acquisition aims to bolster Lilly's immunology pipeline with Morphic's lead molecule, MORF-057, an oral integrin therapy currently in Phase 2 studies for treating ulcerative colitis and Crohn's disease. The transaction has been approved by both companies' boards and is expected to close in Q3 2024, subject to standard conditions. The offer represents a 79% premium to Morphic's stock price as of July 5, 2024. Morphic's board recommends shareholders tender their shares.
Morphic Therapeutic (Nasdaq: MORF) announced its participation in the 2024 Jefferies Global Healthcare Conference. The event will feature a fireside chat with members of the company's management team. The session is scheduled for June 5th at 10:30 AM ET and will be webcast live on Morphic's website, with an archived replay available afterward. Morphic is a biotechnology firm focused on developing oral integrin therapies for chronic diseases.
Morphic Therapeutic (Nasdaq: MORF) presented groundbreaking preclinical data at the Digestive Disease Week 2024, showcasing the real-time visualization of their small molecule α4β7 inhibitor, MT-108, on B cell movement in the gut. Using Spinning Disk Intravital Microscopy (IVM), the study demonstrated that MT-108 significantly increases the velocity and flux of lymphocytes in gut-associated lymphoid tissues (GALT), comparable to the anti-α4β7 antibody DATK32. This inhibition prevents lymphocyte migration into gut tissues, a key factor in inflammatory bowel disease. The data highlights MT-108's potent and selective impact on immune cell trafficking similar to monoclonal antibodies, providing a new avenue for oral integrin therapies.
Morphic Therapeutic (Nasdaq: MORF) will participate in the 2024 RBC Capital Markets Global Healthcare Conference where Dr. Marc Schegerin, COO and CFO, will engage in a fireside chat on May 15th. The company is focused on developing oral integrin therapies for chronic diseases.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.